AirSculpt Technologies (AIRS) investor relations material

Business overview and market positioning

• Provides minimally invasive body contouring, fat removal, fat transfer, and skin tightening using a patented method across 31 offices, targeting affluent consumers aged 35-55 with procedures averaging $12,000-$13,000.

• Positioned as a solution for GLP-1 medication side effects, such as loose skin and stubborn fat, with growing demand from this segment.

• Competitive advantages include a unique, patented process, lower complication rates, rapid recovery, and natural fat transfer options.

Growth drivers and financial performance

• Achieved first positive same-store sales comp in over two years, driven by revamped direct-to-consumer sales and marketing strategies.

• 2024 outlook targets approximately 2.5% same-store sales growth, with momentum from core business stabilization and enhanced marketing.

• Mature clinics average $5 million in annual revenue with 60% gross margins, and new clinics typically reach profitability within six months to a year.

GLP-1 opportunity and service expansion

• GLP-1 usage is projected to rise from 5-6 million to 25-30 million consumers, increasing demand for procedures addressing side effects like loose skin.

• Rolled out standalone skin tightening in all centers and piloted skin removal, with procedures growing from 100 in Q4 to 150 in Q1.

• Skin tightening and removal services are expanding the total addressable market, potentially doubling long-term revenue opportunities.